186 related articles for article (PubMed ID: 32967970)
1. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Jiang TY; Pan YF; Wan ZH; Lin YK; Zhu B; Yuan ZG; Ma YH; Shi YY; Zeng TM; Dong LW; Tan YX; Wang HY
Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967970
[TBL] [Abstract][Full Text] [Related]
2. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Jiang TY; Feng XF; Fang Z; Cui XW; Lin YK; Pan YF; Yang C; Ding ZW; Zhang YJ; Tan YX; Wang HY; Dong LW
Cancer Lett; 2021 Mar; 501():187-199. PubMed ID: 33220333
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract][Full Text] [Related]
4. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death.
Naradun N; Talabnin K; Ayuttha KIN; Talabnin C
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):109-120. PubMed ID: 36227332
[TBL] [Abstract][Full Text] [Related]
7. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
8. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
9. PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis.
Jiang TY; Shi YY; Cui XW; Pan YF; Lin YK; Feng XF; Ding ZW; Yang C; Tan YX; Dong LW; Wang HY
Gastroenterology; 2023 Mar; 164(3):424-438. PubMed ID: 36436593
[TBL] [Abstract][Full Text] [Related]
10. PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK.
Jiang TY; Cui XW; Zeng TM; Pan YF; Lin YK; Feng XF; Tan YX; Yuan ZG; Dong LW; Wang HY
Sci Transl Med; 2023 Jul; 15(704):eadd7464. PubMed ID: 37437018
[TBL] [Abstract][Full Text] [Related]
11. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
Zhu H; Han C; Lu D; Wu T
Am J Pathol; 2014 Oct; 184(10):2828-39. PubMed ID: 25239565
[TBL] [Abstract][Full Text] [Related]
12. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
Serra-Camprubí Q; Verdaguer H; Oliveros W; Lupión-Garcia N; Llop-Guevara A; Molina C; Vila-Casadesús M; Turpin A; Neuzillet C; Frigola J; Querol J; Yáñez-Bartolomé M; Castet F; Fabregat-Franco C; Escudero-Iriarte C; Escorihuela M; Arenas EJ; Bernadó-Morales C; Haro N; Giles FJ; Pozo ÓJ; Miquel JM; Nuciforo PG; Vivancos A; Melé M; Serra V; Arribas J; Tabernero J; Peiró S; Macarulla T; Tian TV
Clin Cancer Res; 2023 Jan; 29(2):432-445. PubMed ID: 36374558
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
14. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
15. RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.
Yu GY; Wang X; Zheng SS; Gao XM; Jia QA; Zhu WW; Lu L; Jia HL; Chen JH; Dong QZ; Lu M; Qin LX
Cell Physiol Biochem; 2018; 47(3):1152-1166. PubMed ID: 29913454
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
[TBL] [Abstract][Full Text] [Related]
17. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Benitez JA; Finlay D; Castanza A; Parisian AD; Ma J; Longobardi C; Campos A; Vadla R; Izurieta A; Scerra G; Koga T; Long T; Chavez L; Mesirov JP; Vuori K; Furnari F
Neuro Oncol; 2021 Jul; 23(7):1072-1086. PubMed ID: 33428749
[TBL] [Abstract][Full Text] [Related]
18. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21.
He Q; Cai L; Shuai L; Li D; Wang C; Liu Y; Li X; Li Z; Wang S
Mol Carcinog; 2013 Apr; 52(4):286-96. PubMed ID: 22213145
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]